Explain this page
Arphra AIPlain-English read on Eli Lilly and Company’s valuation06-08today
- Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026 - marketscreener.com5h
- Is Eli Lilly (NYSE:LLY) Opening A New Growth Chapter? - Kalkine Media5h
- Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy? - Insider Monkey7h
- Lilly declares third-quarter 2026 dividend9h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2,432.81
+120.43% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
2bull14bear
±5% threshold
Analyst PT consensus: $1,266.17 (+14.72%)
Candlestick · 1Y
Open in chart workstation →LLY
1,099+42.55%H 1,183L 623.78MA50 1,011MA200 966.09Avg vol 3.6M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.47% | -1.17% | +3.63% | +21.72% | +2.53% | +2.70% | +43.22% | +141.15% | +398.41% | +1410.44% | +39176.87% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$23.84M
10 txns
Net flow
−$23.84M
Aftermarket
LiveLast trade
$1104.49
383 sh
Bid
$1103.02
1 sh
Ask
$1104.91
5 sh
Spread
$1.890
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.8B | $7.4B | $8.26 |
| Q4 Dec 2025 | $19.29B | $6.64B | $7.39 |
| Q3 Sep 2025 | $17.6B | $5.58B | $6.21 |
| Q2 Jun 2025 | $15.56B | $5.66B | $6.29 |
| Q1 Mar 2025 | $12.73B | $2.76B | $3.06 |
| Q4 Dec 2024 | $13.53B | $4.41B | $4.88 |
Sector & industry today
LiveSectors
- Real Estate+1.28%
- Industrials+1.01%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.03%
- Utilities-0.09%
- Financial Services-0.18%
- Communication Services-0.56%
- Technology-0.77%
- Consumer Cyclical-0.83%
- Consumer Defensive-0.98%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.03%
- Biotechnology+7.27%
- Software - Services-5.92%
- Electronic Gaming & Multimedia-3.76%
- Financial - Mortgages-3.51%
- Software - Infrastructure-3.12%
- Electrical Equipment & Parts+2.70%
- Staffing & Employment Services-2.69%
- Apparel - Footwear & Accessories-2.61%
- Coal-2.36%
- Advertising Agencies+2.35%
- Engineering & Construction+2.33%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$1,266.17
+15.57% upside
Low
$1,119.00
Median
$1,270.00
High
$1,400.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026 - marketscreener.comnews.google.com·Jun 22, 2026
- Is Eli Lilly (NYSE:LLY) Opening A New Growth Chapter? - Kalkine Medianews.google.com·Jun 22, 2026
- Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy? - Insider Monkeynews.google.com·Jun 22, 2026
- Lilly declares third-quarter 2026 dividendgurufocus.com·Jun 22, 2026
- LLY DCF Analysis: Intrinsic Value $762 vs Price $1099 - GuruFocusnews.google.com·Jun 22, 2026
- Lilly declares third-quarter 2026 dividendprnewswire.com·Jun 22, 2026
- Lilly declares third-quarter 2026 dividendprnewswire.com·Jun 22, 2026
- Eli Lilly (LLY) Partners with BioArctic for Neurodegeneration Tr - GuruFocusnews.google.com·Jun 22, 2026
Recent analyst activity
DB- Jun 22, 2026PT$1135.00Eli Lilly price target raised to $1,135 from $1,050 at BerenbergBerenberg Bank
- Jun 22, 2026GradeOverweight → OverweightEli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald as Injectable Obesity TRx DownCantor Fitzgerald
- Jun 15, 2026GradeOutperform → OutperformBMO Capital on Eli Lilly (LLY): 'Early Data for AJ1-11095 Impress at EHA'BMO Capital
- Jun 09, 2026GradeBuy → BuyEli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 09, 2026PT$1350.00Eli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 08, 2026GradeOutperform → OutperformBernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)Bernstein
- Jun 05, 2026GradeOverweight → OverweightMorgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'Morgan Stanley
Financial scores
DBJun 19, 2026Altman Z
9.49
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
6/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
Total assets
$112.48B
Total debt
$42.5B
Cash & equiv
$7.16B
Operating CF
$16.81B
Free cash flow
$8.97B
Buybacks
-$4.11B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 2,208 | $2.2M | May 06, 2026 |
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 13,620 | $13.55M | May 06, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,070 | $1.16M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,322 | $1.45M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 895 | $971.17K | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 930 | $1.01M | Jan 07, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $65.18B | $29.7B | $20.64B | $22.95 | +31.66% |
| FY 2024 | $45.04B | $17.5B | $10.59B | $11.71 | +23.51% |
| FY 2023 | $34.12B | $10.79B | $5.24B | $5.80 | +15.36% |
| FY 2022 | $28.54B | $8.65B | $6.24B | $6.57 | +21.88% |
| FY 2021 | $28.32B | $7.93B | $5.58B | $5.85 | +19.71% |